Dear reader, the story of Purdue Pharma and its drug OxyContin is one of the most painful chapters in modern medical history because it shows how a medicine that starts as a solution for pain can become the door to a massive wave of addiction and deaths across an entire country. The story begins in the mid-1990s, when Purdue launched OxyContin in the US market and presented it to doctors and patients as a strong, long-acting painkiller that could give continuous relief with a “low risk of addiction,” according to the company’s claims. That short phrase, “low risk of addiction”, was the spark on which almost the entire marketing strategy was built, and time proved it to be misleading and dangerous.

OxyContin contains oxycodone, which belongs to the opioid family, medicines used to treat severe pain, such as cancer pain or pain after major surgery. The problem with these drugs, dear reader, is that they have two faces: on one side, they are very effective at relieving intense pain when other medicines don’t work; on the other side, they carry a high risk of addiction, and high doses can suppress breathing and cause death. Purdue promoted OxyContin as a “controlled-release” tablet that releases the drug slowly over 12 hours and claimed that this slow release reduces the chance of addiction compared with fast-acting opioids. But there was no strong scientific evidence to support this claim in the way the company suggested.

At that time, the medical mood in the United States was shifting. Pain was being talked about as the “fifth vital sign,” and hospitals and patient groups were putting more and more pressure on doctors to do something about pain and to make sure patients were not left suffering. In this environment, Purdue saw its opportunity. It built an army of sales representatives who visited doctors and clinics constantly, carrying brochures, giving “educational” talks, offering meals and small gifts, and repeating one message over and over: if OxyContin is used as prescribed, the risk of addiction is very low. Many doctors believed this message, thinking it was based on solid research, when in reality it was built on weak data and inappropriate sources.

The company did not stop at serious cases like cancer pain. It pushed hard to use OxyContin for common chronic pains: back pain, joint pain, and other orthopedic problems. This changed the drug’s role from a heavy painkiller that should be used with extreme caution into a relatively “normal” option for long-term pain in large numbers of patients. The result was an explosion in prescriptions: millions of pills were being written every year, spreading into homes, pharmacies, and communities across America.

At first, everything looked official and legal: a doctor writes a prescription, a pharmacy dispenses the drug, and a well-known company stands behind the product. But over time, problems started to appear. Some patients developed tolerance, meaning their bodies no longer responded to the usual dose, so they needed higher and higher doses to get the same relief. Others learned that if they crushed or dissolved the tablets, the slow-release mechanism disappeared and the pill turned into one big dose that produced an intense “rush” similar to heroin. As these tricks spread from person to person, OxyContin started to be widely abused. Pills were stolen from medicine cabinets at home, sold on the street, and shifted from being a prescription medicine into a street drug in some communities.

At the same time, the numbers began to climb: rising cases of addiction, more overdoses, more deaths linked to opioids, including OxyContin. Although warning signs were clear, many accuse Purdue of continuing for years to minimize the risks and to market the drug aggressively. Regulators such as the US Food and Drug Administration (FDA) were also not strict enough in the early years. The warnings on the drug’s label did not fully reflect the dangers of long-term use. Later on, the warnings were strengthened, but by then the damage had already spread.

The crisis grew into what is now called the opioid epidemic in the United States. Many people found themselves addicted to medicines prescribed initially by their own doctors for pain. When authorities and health agencies started tightening rules on opioid prescribing, some patients turned to the black market to get cheaper and more available alternatives like heroin. Then came fentanyl, a potent synthetic opioid, and overdose deaths shot up to tens of thousands per year. Today, fentanyl is the main cause of these deaths, but as many experts say, the starting point was the massive over-prescribing of prescription opioids, with OxyContin at the center.

Facing this harsh reality, Purdue Pharma and the Sackler family that owned it were hit by a wave of lawsuits from states, cities, Native American tribes, health institutions, and families of victims. Documents and investigations showed that the company had deliberately downplayed the risk of addiction and promoted an overly comforting and inaccurate image of the drug’s long-term safety. In 2007, a branch of the company and several top executives admitted, in a criminal settlement, to misleading marketing and paid hundreds of millions of dollars in fines. But that did not stop the lawsuits, which continued and grew bigger.

In 2019, under huge financial and legal pressure, Purdue filed for bankruptcy. The goal was not to shut down overnight, but to use bankruptcy law to consolidate thousands of cases into a single process and reach a global settlement, with billions of dollars directed to treatment programs, prevention efforts, and support for affected communities. Proposed plans included the Sackler family giving up ownership of the company and turning Purdue into a “public benefit” entity focused on addiction treatment and overdose reversal medicines, with profits going to communities rather than previous owners. Nevertheless, some parts of the deal, especially the terms that would protect the family from future lawsuits, sparked public anger. After negotiations and changes, a revised settlement worth billions of dollars was approved, though the moral debate around it continues.

Dear reader, if we want to summarize the lesson from this story, we can say it is a global warning about the moment when a patient is treated as a “market” and pain becomes a “business opportunity.” When misleading marketing, pressure on doctors, weak early regulation, and people’s real need for relief all mix together, the result can be disastrous. The story of Purdue and OxyContin is not just a chapter in the history of one drug; it is a loud alarm for health systems everywhere about the danger of letting marketing drive treatment decisions without a real balance between the patient’s well-being and commercial profit.

nabilalhakamy@